<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2485">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556280</url>
  </required_header>
  <id_info>
    <org_study_id>CA-0005</org_study_id>
    <nct_id>NCT03556280</nct_id>
  </id_info>
  <brief_title>Multi-Center Study of Sensory Stimulation to Improve Brain Function</brief_title>
  <acronym>Overture</acronym>
  <official_title>Multi-Center Study of Sensory Stimulation to Improve Brain Function (Overture Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cognito Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cognito Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Overture Study is a randomized, controlled, single-blind multi-center clinical trial&#xD;
      using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people&#xD;
      with mild to moderate cognitive impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Overture Study (CA-0005) is a Phase I/II randomized, controlled, single-blind&#xD;
      multi-center clinical trial using the GammaSense Stimulation device to study safety,&#xD;
      adherence rates and efficacy in subjects with mild to moderate cognitive impairment (MMSE&#xD;
      14-26) who are age 55 and older.&#xD;
&#xD;
      Subjects who pass screening will be randomized (ratio 2:1 Treatment to Control). Subjects and&#xD;
      their caregivers will be blinded to their randomization group, as will key raters at each&#xD;
      site. The device will be used for 60 minutes daily during the 6-month therapy phase, followed&#xD;
      by a one month safety follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>Quarterly over 6 months</time_frame>
    <description>A widely accepted, validated measure of cognitive function in Alzheimer's Disease consisting of 14 questions that result in a score ranging from 0 to 90 with higher scores representing greater cognitive impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amyloid PET/CT</measure>
    <time_frame>Quarterly over 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Dementia Alzheimers</condition>
  <condition>Dementia, Mild</condition>
  <condition>Dementia, Alzheimer Type</condition>
  <condition>Dementia of Alzheimer Type</condition>
  <condition>Dementia</condition>
  <condition>Cognitive Impairment, Mild</condition>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will use the Active GammaSense Stimulation System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Will use the Sham GammaSense Stimulation System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GammaSense Stimulation System (Active Settings)</intervention_name>
    <description>Proprietary auditory and visual sensory stimulation device.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GammaSense Stimulation System (Sham Settings)</intervention_name>
    <description>Proprietary auditory and visual sensory stimulation device.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;= 55 Years old&#xD;
&#xD;
          -  MMSE 14-26&#xD;
&#xD;
          -  Prodromal Alzheimer's Disease (AD), AD or Mild Cognitive Impairment (MCI) due to AD&#xD;
&#xD;
          -  Participation of a caregiver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Profound hearing or visual impairment&#xD;
&#xD;
          -  Seizure Disorder&#xD;
&#xD;
          -  Use of memantine (Namenda or Namzaric)&#xD;
&#xD;
          -  Implantable devices (non-MR compatible)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research, Inc</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Center for Memory</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cognitive and Research Center of New Jersey</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Cognitive Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

